Company: TAK
Filing Date: 2025-06-26
Form Type: 424B5
Source: 0001395064-25-000101
Chunk: 17

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-26
Form: 424B5
Chunk 17
---
 to be July 8, 2025.

(4) Represents the sum of long-term debt and total equity.

Except as disclosed above, there has been no material change in Takeda’s consolidated capitalization and indebtedness since March 31, 2025.

<div align='center'>S-11</div>

### SELECTED FINANCIAL AND OTHER INFORMATION
The following table presents selected financial information as of and for the fiscal years ended March 31, 2021, 2022, 2023, 2024 and 2025, which is derived from Takeda’s consolidated financial statements as of and for the same periods. These financial statements are prepared in accordance with IFRS.

The consolidated financial statements of Takeda Pharmaceutical Company Limited and its subsidiaries included in Takeda’s most recent annual report on Form 20-F for the fiscal year ended March 31, 2025, which is incorporated herein by reference, have been audited in accordance with the standards of the Public Company Accounting Oversight Board (United States) by KPMG AZSA LLC, Takeda’s independent registered public accounting firm.

You should read the selected consolidated financial information presented below together with the information included in “Item 5. Operating and Financial Review and Prospects” and the audited consolidated financial statements, including the notes thereto, in Takeda’s most recent annual report on Form 20-F, which is incorporated herein by reference. The information presented below is qualified in its entirety by reference to that information.

<div align='center'>S-12</div>

|                                                                                  |     |                As of or for the fiscal year ended March 31, 
                                                        2021 |          |     |         2022 |          |     |         2023 |          |     |         2024 |          |     | 2025         |          |       |
|:---------------------------------------------------------------------------------|:----|------------------------------------------------------------:|---------:|:----|-------------:|---------:|:----|-------------:|---------:|:----|-------------:|---------:|:----|:-------------|---------:|------:|
|                                                                                  |     | -billions of yen, except share and per share data and where 
                                   designated as U.S. dollar |          |     |              |          |     |              |          |     |              |          |     |              |          |       |
| Selected Statements of Profit or Loss Data:                                      |     |